- Credit Suisse upgrades biotech, pharma and life sciences to Overweight citing attractive valuations in large caps, modestly positive money flow into healthcare sector funds and stabilizing of revision trends.
- On the negative side, valuations in healthcare small caps appear bullish and relative performance may be pressured by a rise in interest rates.
- IBB,BIB,PJP,PPH,IHI,XHE,BBP,XLV,FBT,FHLC,BBP,IHF